• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by 23andMe Holding Co.

    2/14/23 6:08:37 AM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ME alert in real time by email
    SC 13G 1 tm235872d5_sc13g.htm SC 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Schedule 13G
    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b)

    (Amendment No. ___________)*

     

    23andMe Holding Co.

    (Name of Issuer)

     

    Class A Common Stock, par value $0.0001

    (Title of Class of Securities)

     

    90138Q108

    (CUSIP Number)

     

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨   Rule 13d-1(b)

     

    ¨   Rule 13d-1(c)

     

    x   Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    (Continued on following pages)

     

    Page 1 of 10

     

    Exhibit Index on Page 9

     

     

     

     

     

    CUSIP # 90138Q108Page 2 of 10

     

    1 NAME OF REPORTING PERSONS                 NewView Capital Fund I, L.P. (“NVC Fund I”)
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)         ¨         (b)         x

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON
    WITH
    5

    SOLE VOTING POWER
    19,455,681 shares, except that NewView Capital Partners I, LLC (“NVC Partners I”), the general partner of NVC Fund I, may be deemed to have sole power to vote these shares, and Ravi Viswanathan (“Viswanathan”), the managing member of NVC Partners I, may be deemed to have sole power to vote these shares.

     

    6 SHARED VOTING POWER
    See response to row 5.
    7

    SOLE DISPOSITIVE POWER

    19,455,681 shares, except that NVC Partners I, the general partner of NVC Fund I, may be deemed to have sole power to dispose of these shares, and Viswanathan, the managing member of NVC Partners I, may be deemed to have sole power to dispose of these shares.

     

    8 SHARED DISPOSITIVE POWER
    See response to row 7.
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 19,455,681
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    6.8%
    12 TYPE OF REPORTING PERSON PN

     

     

     

     

    CUSIP # 90138Q108Page 3 of 10

     

    1 NAME OF REPORTING PERSONS                 NewView Capital Partners I, LLC (“NVC Partners I”)
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)         ¨         (b)         x

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON
    WITH
    5

    SOLE VOTING POWER
    19,455,681 shares, all of which shares are directly owned by NewView Capital Fund I, L.P. (“NVC Fund I”). NVC Partners I, the general partner of NVC Fund I, may be deemed to have sole power to vote these shares, and Ravi Viswanathan (“Viswanathan”), the managing member of NVC Partners I, may be deemed to have sole power to vote these shares.

     

    6 SHARED VOTING POWER
    See response to row 5.
    7

    SOLE DISPOSITIVE POWER

    19,455,681 shares, all of which shares are directly owned by NVC Fund I. NVC Partners I, the general partner of NVC Fund I, may be deemed to have sole power to dispose of these shares, and Viswanathan, the managing member of NVC Partners I, may be deemed to have sole power to dispose of these shares.

     

    8 SHARED DISPOSITIVE POWER
    See response to row 7.
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 19,455,681
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    6.8%
    12 TYPE OF REPORTING PERSON OO

     

     

     

     

    CUSIP # 90138Q108Page 4 of 10

     

    1 NAME OF REPORTING PERSONS                 Ravi Viswanathan (“Viswanathan”)
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)         ¨         (b)         x

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON
    WITH
    5

    SOLE VOTING POWER
    19,455,681 shares, all of which shares are directly owned by NewView Capital Fund I, L.P. (“NVC Fund I”). Viswanathan is the managing member of NewView Capital Partners I, LLC (“NVC Partners I”), which is the general partner of NVC Fund I. Viswanathan may be deemed to have sole power to vote these shares.

     

    6 SHARED VOTING POWER
    See response to row 5.
    7

    SOLE DISPOSITIVE POWER

    19,455,681 shares, all of which shares are directly owned by NVC Fund I. Viswanathan is the managing member of NVC Partners I, which is the general partner of NVC Fund I. Viswanathan may be deemed to have sole power to dispose of these shares.

     

    8 SHARED DISPOSITIVE POWER
    See response to row 7.
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 19,455,681
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    6.8%
    12 TYPE OF REPORTING PERSON IN

     

     

     

     

    CUSIP # 90138Q108Page 5 of 10

     

    ITEM 1(A).NAME OF ISSUER

     

    23andMe Holding Co. (the “Issuer”)

     

    ITEM 1(B).ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES

     

    349 Oyster Point Boulevard

    South San Francisco, California 94080

     

    ITEM 2(A).NAME OF PERSONS FILING

     

    This Schedule is filed by NewView Capital Fund I, L.P., a Delaware limited partnership (“NVC Fund I”), NewView Capital Partners I, LLC, a Delaware limited liability company (“NVC Partners I”), and Ravi Viswanathan (“Viswanathan”). The foregoing entities and individuals are collectively referred to as the “Reporting Persons.”

     

    ITEM 2(B).ADDRESS OF PRINCIPAL OFFICE

     

    The address for each of the Reporting Persons is:

     

    c/o NewView Capital Management, LLC

    1201 Howard Avenue, Suite 101
    Burlingame, California 94010

     

    ITEM 2(C).CITIZENSHIP

     

    See Row 4 of cover page for each Reporting Person.

     

    ITEM 2(D).

    TITLE OF CLASS OF SECURITIES

     

    Class A Common Stock, par value $0.0001

     

    ITEM 2(E)CUSIP NUMBER

     

    90138Q108

     

    ITEM 3.

    If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    ITEM 4.OWNERSHIP

     

    The following information with respect to the ownership of the Common Stock of the Issuer by the persons filing this Statement is provided as of December 31, 2022 (based on 286,738,037 shares of Class A common stock outstanding as of October 31, 2022 as reported by the Issuer in its Form 10-Q for the quarterly period ended September 30, 2022):

     

     

     

     

    CUSIP # 90138Q108Page 6 of 10

     

    (a)Amount beneficially owned:

    See Row 9 of cover page for each Reporting Person.

     

    (b)Percent of Class:

    See Row 11 of cover page for each Reporting Person.

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote:

    See Row 5 of cover page for each Reporting Person.

     

    (ii)Shared power to vote or to direct the vote:

     

    See Row 6 of cover page for each Reporting Person.

     

    (iii)Sole power to dispose or to direct the disposition of:

     

    See Row 7 of cover page for each Reporting Person.

     

    (iv)Shared power to dispose or to direct the disposition of:

    See Row 8 of cover page for each Reporting Person.

     

    ITEM 5.OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

    Not applicable.

     

    ITEM 6.OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

    Under certain circumstances set forth in the limited partnership agreement of NVC Fund I and the limited liability company agreement of NVC Partners I, the partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from the sale of, shares of the Issuer directly or indirectly owned by each such entity of which they are a partner or member.

     

    ITEM 7.IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

    Not applicable.

     

    ITEM 8.IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

    Not applicable

     

    ITEM 9.NOTICE OF DISSOLUTION OF GROUP.

    Not applicable

     

     

     

     

    CUSIP # 90138Q108Page 7 of 10

     

    ITEM 10.CERTIFICATION.

    Not applicable

     

     

     

     

    CUSIP # 90138Q108Page 8 of 10

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 14, 2023

     

      NEWVIEW CAPITAL FUND I, L.P.
       
      By: NEWVIEW CAPITAL PARTNERS I, LLC
      Its: General Partner
       
      By: /s/ Ravi Viswanathan
      Name: Ravi Viswanathan
      Title: Managing Member
       
      NEWVIEW CAPITAL PARTNERS I, LLC
       
      By: /s/ Ravi Viswanathan
      Name: Ravi Viswanathan
      Title: Managing Member
       
      RAVI VISWANATHAN
       
      By: /s/ Ravi Viswanathan
      Name: Ravi Viswanathan

     

     

     

     

    CUSIP # 90138Q108Page 9 of 10

     

    EXHIBIT INDEX

     

      Found on
    Sequentially
    Exhibit Numbered Page
       
    Exhibit A:  Agreement of Joint Filing 10

     

     

     

     

    CUSIP # 90138Q108Page 10 of 10

     

    exhibit A

     

    Agreement of Joint Filing

     

    The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock of the Issuer shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G.

     

    Date: February 14, 2023

     

      NEWVIEW CAPITAL FUND I, L.P.
       
      By: NEWVIEW CAPITAL PARTNERS I, LLC
      Its: General Partner
       
      By: /s/ Ravi Viswanathan
      Name: Ravi Viswanathan
      Title: Managing Member
       
      NEWVIEW CAPITAL PARTNERS I, LLC
       
      By: /s/ Ravi Viswanathan
      Name: Ravi Viswanathan
      Title: Managing Member
       
      RAVI VISWANATHAN
       
      By: /s/ Ravi Viswanathan
      Name: Ravi Viswanathan

     

     

     

    Get the next $ME alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ME

    DatePrice TargetRatingAnalyst
    11/29/2022$7.00Buy
    Berenberg
    9/22/2022$6.00Outperform
    Cowen
    2/11/2022$14.00 → $11.00Outperform
    Credit Suisse
    12/20/2021$13.00 → $9.00Neutral
    Citigroup
    11/15/2021$12.00 → $13.00Buy → Neutral
    Citigroup
    11/11/2021$13.00 → $14.00Outperform
    Credit Suisse
    8/17/2021$13.00Outperform
    Credit Suisse
    7/12/2021$14.00Buy
    Citigroup
    More analyst ratings

    $ME
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Kvarda Matthew

    3 - 23andMe Holding Co. (0001804591) (Issuer)

    3/26/25 4:38:00 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Walper Thomas B.

    3 - 23andMe Holding Co. (0001804591) (Issuer)

    3/26/25 4:35:46 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial & Actng Ofcr Selsavage Joseph Anthony covered exercise/tax liability with 5,654 shares, decreasing direct ownership by 6% to 96,468 units (SEC Form 4)

    4 - 23andMe Holding Co. (0001804591) (Issuer)

    2/21/25 5:05:56 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ME
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    23andMe Confirms All Potential Buyers Must Agree to Comply With Privacy Policy and Applicable Law

    SAN FRANCISCO, March 26, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. ("23andMe" or the "Company") (NASDAQ:ME), a leading human genetics and biotechnology company, today announced that it has received approvals from the U.S. Bankruptcy Court for the Eastern District of Missouri (the "Court") for its "first day" motions related to 23andMe's voluntary Chapter 11 petitions filed March 23, 2025, including authorization to pay employee wages and benefits and compensate certain vendors and suppliers in the ordinary course for goods and services provided and to enter into the binding term sheet for a $35 million debtor-in-possession financing facility from JMB Capital Partners (the "DIP Facility"

    3/26/25 6:57:42 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    23andMe Initiates Voluntary Chapter 11 Process to Maximize Stakeholder Value Through Court-Supervised Sale Process

    Intends to use Proceedings to Conduct a Value-Maximizing Sale Process and Resolve Liabilities Company Expects to Continue Business Operations in the Ordinary Course During Proceedings; Secures Commitment for Approximately $35 Million in DIP Financing to Support Ongoing Operations No Changes to Customer Data Management and Access; Company Remains Committed to Transparency Around Customer Data Privacy; Any Buyer will be Required to Comply with Applicable Law with Respect to Treatment of Customer Data Company Announces Board and Leadership Changes to Support Restructuring and Sale Process SAN FRANCISCO, March 23, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. ("23andMe" or the "Company") (

    3/23/25 11:08:03 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    23andMe Launches New Homocysteine (MTHFR-Related) Genetic Report and Accompanying Lab Test

    SAN FRANCISCO, March 21, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics company with a mission to help people access, understand, and benefit from the human genome, today released a new report on the genetics of homocysteine levels for 23andMe+ Premium members, as well as a blood test for next steps in further understanding said levels for an additional fee. One of the top 23andMe customer requested reports, it informs users if they are at a higher likelihood of developing slightly elevated homocysteine levels along with actionable lifestyle factors that can reduce their chances. Homocysteine is an amino acid that plays a key role in important process

    3/21/25 7:30:00 AM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ME
    SEC Filings

    View All

    SEC Form 8-K filed by 23andMe Holding Co.

    8-K - 23andMe Holding Co. (0001804591) (Filer)

    3/28/25 4:09:11 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    23andMe Holding Co. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - 23andMe Holding Co. (0001804591) (Filer)

    3/24/25 6:23:28 AM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by 23andMe Holding Co.

    10-Q - 23andMe Holding Co. (0001804591) (Filer)

    2/6/25 4:27:52 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ME
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Berenberg initiated coverage on 23andMe with a new price target

    Berenberg initiated coverage of 23andMe with a rating of Buy and set a new price target of $7.00

    11/29/22 7:24:54 AM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cowen initiated coverage on 23andMe with a new price target

    Cowen initiated coverage of 23andMe with a rating of Outperform and set a new price target of $6.00

    9/22/22 7:20:18 AM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Credit Suisse reiterated coverage on 23andMe Holding with a new price target

    Credit Suisse reiterated coverage of 23andMe Holding with a rating of Outperform and set a new price target of $11.00 from $14.00 previously

    2/11/22 8:14:04 AM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ME
    Leadership Updates

    Live Leadership Updates

    View All

    23andMe Appoints Three New Independent Directors to Board

    SUNNYVALE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (the "Company" or "23andMe"), a leading human genetics and preventive health company, today announced the appointments of Andre Fernandez, Jim Frankola, and Mark Jensen, three accomplished and experienced executives, as independent members of the Company's Board of Directors (the "Board"), effective on October 28, 2024. Each of Mr. Fernandez, Mr. Frankola, and Mr. Jensen have been appointed to serve as members of the Board's Audit Committee and Compensation Committee, with Mr. Fernandez serving as the Chair of the Audit Committee and Mr. Jensen serving as the Chair of the Compensation Committee. In additio

    10/29/24 7:30:00 AM ET
    $ANSS
    $CDLX
    $LSCC
    Computer Software: Prepackaged Software
    Technology
    Computer Software: Programming Data Processing
    Semiconductors

    Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

    Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4

    12/12/23 5:31:00 PM ET
    $EXAS
    $ILMN
    $LAB
    Medical Specialities
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Reza Afkhami Joins 23andMe as Chief Corporate Development Officer

    SOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) ("23andMe"), a leading human genetics and biopharmaceutical company, today announced the appointment of Reza Afkhami as its Chief Corporate Development Officer overseeing corporate development efforts across its therapeutics, research services and consumer groups. Afkhami will be responsible for spearheading and driving a wide range of industry collaborations for the Company. 23andMe Therapeutics has a pipeline of genetically validated discovery and clinical programs, which it intends to advance through collaborations with pharmaceutical companies. Furthermore, 23andMe hopes to help the pharmac

    5/8/23 7:00:00 AM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ME
    Financials

    Live finance-specific insights

    View All

    23andMe Reports Second Quarter Fiscal Year 2025 Financial Results

    SUNNYVALE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and preventive health company, reported its financial results for the second quarter of fiscal year 2025 (FY25), which ended September 30, 2024. Key Results: Improved GAAP Net Loss by 21% and Adjusted EBITDA by 26% for the same period in the prior year (see important additional information below).The 23andMe comprehensive Total Health longevity service is now available to all customers, combining whole exome genetic sequencing with bi-annual lab tests for 55+ key blood biomarkers, and expert clinicians trained in genetics-informed preventive care and health action p

    11/12/24 7:30:00 AM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CORRECTION - 23andMe to Report Q2 FY2025 Financial Results

    SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- An earlier release under the same headline should have noted 23andMe Holding Co. (NASDAQ:ME) (23andMe) will report financial results for the second quarter of fiscal year 2025 (FY2025) prior to the market opening on Tuesday, November 12, 2024 (the prior release incorrectly stated the results would be reported after the market closes). The Company will webcast a conference call at 8:00 a.m. Eastern Time on that date to discuss the quarter's results and report on business progress. The webcast can be accessed on the day of the event at this link. A webcast replay will be available at the same address following the event. In addition, 23

    11/7/24 5:54:12 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    23andMe to Report Q2 FY2025 Financial Results

    SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (23andMe), a leading human genetics and biopharmaceutical company, announced today that it will report financial results for the second quarter of fiscal year 2025 (FY2025) after the market closes on Tuesday, November 12, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter's results and report on business progress. The webcast can be accessed on the day of the event at this link. A webcast replay will be available at the same address following the event. In addition, 23andMe will use the Say Technologies platform to allow retail and institutional

    11/7/24 7:30:00 AM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ME
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by 23andMe Holding Co.

    SC 13D/A - 23andMe Holding Co. (0001804591) (Subject)

    11/15/24 4:48:20 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by 23andMe Holding Co.

    SC 13D/A - 23andMe Holding Co. (0001804591) (Subject)

    11/15/24 4:20:24 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by 23andMe Holding Co.

    SC 13G - 23andMe Holding Co. (0001804591) (Subject)

    11/13/24 6:00:29 AM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care